Cargando…

Cholinergic immunomodulation in inflammatory bowel diseases

Inflammatory bowel diseases (IBD) are chronic intestinal disorders characterized by dysregulated immune responses to resident microbiota in genetically susceptible hosts. The activation of the cholinergic system has been proposed for the treatment of IBD patients according to its potential anti-infl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Serafini, Michele A., Paz, Ana H., Nunes, Natalia S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683952/ https://www.ncbi.nlm.nih.gov/pubmed/34977822 http://dx.doi.org/10.1016/j.bbih.2021.100401

Ejemplares similares

Evidence-Based Approach to the Discontinuation of Immunomodulators or Biologics in Inflammatory Bowel Disease
por: Miyatani, Yusuke, et al.
Publicado: (2023)

Adrenergic/Cholinergic Immunomodulation in the Rat Model—In Vivo Veritas?
por: Rinner, I., et al.
Publicado: (1998)

Tailoring Biologic or Immunomodulator Treatment Withdrawal in Inflammatory Bowel Disease
por: Louis, Edouard
Publicado: (2020)

The Effect of In Utero Exposure to Maternal Inflammatory Bowel Disease and Immunomodulators on Infant Immune System Development and Function
por: Prentice, Ralley E., et al.
Publicado: (2023)

Updates on conventional therapies for inflammatory bowel diseases: 5-aminosalicylates, corticosteroids, immunomodulators, and anti-TNF-α
por: Park, Jihye, et al.
Publicado: (2022)

A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment
por: Marotti, Valentina, et al.
Publicado: (2023)

Declining use of combination infliximab and immunomodulator for inflammatory bowel disease in the community setting
por: Berkowitz, Joshua C, et al.
Publicado: (2018)

Dose Escalation Assessment Among Targeted Immunomodulators in the Management of Inflammatory Bowel Disease
por: Ehrenberg, Rahel, et al.
Publicado: (2020)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

Therapeutic ultrasound attenuates DSS-induced colitis through the cholinergic anti-inflammatory pathway
por: Nunes, Natalia Schneider, et al.
Publicado: (2019)

Inflammatory Burden and Immunomodulative Therapeutics of Cardiovascular Diseases
por: Kao, Ting-Wei, et al.
Publicado: (2022)

The efficacy of immunomodulators in the prevention and suppression of anti-drug antibodies to anti-tumor necrosis factor therapy in inflammatory bowel disease
por: Fousekis, Fotios S., et al.
Publicado: (2022)

Immunomodulation and Generation of Tolerogenic Dendritic Cells by Probiotic Bacteria in Patients with Inflammatory Bowel Disease
por: Ghavami, Shaghayegh Baradaran, et al.
Publicado: (2020)

The Cholinergic and Adrenergic Autocrine Signaling Pathway Mediates Immunomodulation in Oyster Crassostrea gigas
por: Liu, Zhaoqun, et al.
Publicado: (2018)

Systematic review with meta‐analysis: the effects of immunomodulator or biological withdrawal from mono‐ or combination therapy in inflammatory bowel disease
por: Dohos, Dóra, et al.
Publicado: (2020)

Drug Targeting of Inflammatory Bowel Diseases by Biomolecules
por: Antunes, Joana Costa, et al.
Publicado: (2021)

Cholinergic Anti-Inflammatory Pathway and the Liver
por: Hajiasgharzadeh, Khalil, et al.
Publicado: (2017)

Nutritional Aspects in Inflammatory Bowel Diseases
por: Balestrieri, Paola, et al.
Publicado: (2020)

A Pooled Analysis of Infections, Malignancy, and Mortality in Infliximab- and Immunomodulator-Treated Adult Patients With Inflammatory Bowel Disease
por: Lichtenstein, Gary R, et al.
Publicado: (2012)

Role of the Cholinergic Anti-Inflammatory Reflex in Central Nervous System Diseases
por: Ramos-Martínez, Ivan Emmanuel, et al.
Publicado: (2021)

Pharmacological and Electroceutical Targeting of the Cholinergic Anti-Inflammatory Pathway in Autoimmune Diseases
por: Zouali, Moncef
Publicado: (2023)

Immunomodulation and Anti-Inflammatory Effects of Garlic Compounds
por: Arreola, Rodrigo, et al.
Publicado: (2015)

Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?
por: Macaluso, Fabio Salvatore, et al.
Publicado: (2021)

Immunomodulating Activity and Therapeutic Effects of Short Chain Fatty Acids and Tryptophan Post-biotics in Inflammatory Bowel Disease
por: Russo, Edda, et al.
Publicado: (2019)

Impact of treatment with immunomodulators and tumour necrosis factor antagonists on the incidence of infectious events in patients with inflammatory bowel disease
por: Andersson, Per, et al.
Publicado: (2022)

Melatonin and multiple sclerosis: antioxidant, anti-inflammatory and immunomodulator mechanism of action
por: Muñoz-Jurado, Ana, et al.
Publicado: (2022)

Immunomodulators in the Rheumatic Diseases
por: Evans, Janine
Publicado: (1991)

Cholinergic Polarization of Human Macrophages
por: Roa-Vidal, Natalia, et al.
Publicado: (2023)

Curcumin-Based Nanomedicines in the Treatment of Inflammatory and Immunomodulated Diseases: An Evidence-Based Comprehensive Review
por: Laurindo, Lucas Fornari, et al.
Publicado: (2023)

Schistosome immunomodulators
por: Acharya, Sreemoyee, et al.
Publicado: (2021)

The Bowel Microbiota and Inflammatory Bowel Diseases
por: Tannock, Gerald W.
Publicado: (2010)

Sulfasalazine as an Immunomodulator of the Inflammatory Process during HIV-1 Infection
por: Feria-Garzón, Manuel G., et al.
Publicado: (2019)

The Cholinergic Anti-Inflammatory Response and the Role of Macrophages in HIV-Induced Inflammation
por: Delgado-Vélez, Manuel, et al.
Publicado: (2018)

Anti-inflammatory and immunomodulating effects of clarithromycin in patients with cystic fibrosis lung disease.
por: Pukhalsky, Alexander L, et al.
Publicado: (2004)

(Poly)phenols in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Review
por: Hagan, Marilyn, et al.
Publicado: (2021)

Immunomodulation and Disease Tolerance to Staphylococcus aureus
por: Li, Zhigang, et al.
Publicado: (2015)

Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease
por: Hong, Seung Wook, et al.
Publicado: (2021)

Effects of anti-TNF therapy and immunomodulators on anxiety and depressive symptoms in patients with inflammatory bowel disease: a 5-year analysis
por: Siebenhüner, Alexander R., et al.
Publicado: (2021)

Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease
por: Stallhofer, Johannes, et al.
Publicado: (2023)

Immunomodulators for Asthma
por: Dimov, Vesselin V, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_mubrhc6kiipvo121kvgb21rd7t